Revenue

With 175 million lenses implanted, Alcon solidifies its market leadership. Discover the technology giving patients unprecedented freedom from glasses.

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

A $1M deal offers a sliver of recovery for victims of the $71M William Jordan Ponzi scheme, putting custodian Kingdom Trust's alleged role in focus.

Amid soaring uranium prices, Refined Energy begins its maiden drill program in Saskatchewan's prolific Athabasca Basin, a high-stakes bet on nuclear's future.

With a $6B M&A war chest and a new AI focus, Roper Technologies takes the stage at Morgan Stanley. Here’s what investors will be watching for.

A new era in hearing arrives with Cochlear's Nexa System, the world's first upgradeable implant, tackling India's vast auditory health challenges.

In a strategic reverse merger with Rallybio, T-cell therapy innovator Candid Therapeutics secures over $505M to advance its groundbreaking autoimmune pipeline.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

Total Joint Orthopedics surpasses 50,000 implants, signaling a major shift as surgeries move from hospitals to efficient, cost-effective surgery centers.

In a strategic move, CCC Intelligent Solutions adds former Salesforce and Informatica exec John Schweitzer to its board, signaling a major push in AI and data.

SaaS growth expert Eric Shoemaker takes the helm at Keebo, aiming to scale its AI-powered platform amid soaring enterprise demand for cloud cost control.

As its Reliquias mine restart nears, Silver Mountain launches a major drill campaign at Caudalosa, aiming to capitalize on a bullish silver market.

Amid rising costs, Chuck E. Cheese offers a $49.99 all-inclusive family deal, challenging competitors who average over $125 for a similar outing.

As Middle East conflict roiled markets, 24/7 on-chain gold offered an immediate safe haven, challenging the dominance of traditional financial systems.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Fidelis Insurance Group completes a $163M repurchase of all shares from founding investor CVC, a move set to boost shareholder value ahead of its rebrand.

Leaders at PDAC 2026 forge a national strategy linking small modular reactors with critical minerals to secure Canada's energy and economic future.

Neogen divests its pioneering genomics business for $160M to slash debt, while Zoetis bolsters its dominance in the animal health diagnostics market.

Zoetis is acquiring Neogen's genomics unit for $160M, a strategic move set to accelerate data-driven innovation in livestock and companion animal care.

As Mike Eastwood retires, new CFO Gary Bischoping, a tech and finance veteran, is set to guide the company's ambitious AI transformation and next chapter of growth.